Xbrane And Stada Celebrate Major Milestone With EU Filing For Lucentis Rival
Xlucane Asset Joins Bioeq/Formycon FYB201 Biosimilar With EMA
Xbrane Biopharma has taken a key step on its journey to begin generating cash from operations by early 2024 at the latest, after its Xlucane biosimilar ranibizumab asset was submitted to the European Medicines Agency by co-development and commercialization partner Stada.
